Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients With Soft Tissue Sarcoma

NCT02267083 is registered in ClinicalTrials.gov with Gem Pharmaceuticals as lead sponsor.

NCT NCT02267083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02267083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients With Soft Tissue Sarcoma
Lead sponsor
Gem Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
January 7, 2015
Completion date
August 18, 2016
Enrollment
22 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcoma